NCT03024879

Brief Summary

In this study, the investigators aimed at evaluating the role of motilin in the regulation of food intake. Motilin, a gastrointestinal hormone, is a hunger signal in healthy volunteers and is significantly increased in obese patients. Its role in food intake regulation might contribute to the pathogenesis of obesity.

Trial Health

53
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
15

participants targeted

Target at below P25 for phase_4 healthy

Timeline
Completed

Started Mar 2014

Longer than P75 for phase_4 healthy

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2014

Completed
2.2 years until next milestone

First Submitted

Initial submission to the registry

May 23, 2016

Completed
8 months until next milestone

First Posted

Study publicly available on registry

January 19, 2017

Completed
8.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2025

Completed
Last Updated

July 10, 2024

Status Verified

July 1, 2024

Enrollment Period

11 years

First QC Date

May 23, 2016

Last Update Submit

July 9, 2024

Conditions

Keywords

MotilinErythromycinFood intake

Outcome Measures

Primary Outcomes (1)

  • Change in food intake, assessed by caloric intake, after intravenous administration of erythromycin compared to placebo

    Caloric intake will be assessed 1 hour after the start of infusion and the start of ad libitum food intake

Secondary Outcomes (1)

  • Frequency of food intake correlated with motilin plasma levels

    Assessment will be done over a period of 5 hours

Study Arms (2)

Erythromycin

ACTIVE COMPARATOR

40 mg of erythromycin will be administered intravenously over a period of 20 min in a saline solution of 100 ml

Drug: Erythromycin

Placebo

PLACEBO COMPARATOR

a saline solution of 100 ml will be administered intravenously over a period of 20 min

Drug: Saline

Interventions

Erythromycin
SalineDRUG
Placebo

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • BMI \< 30 kg/m² for lean volunteers
  • BMI \> 30 kg/m² for obese volunteers
  • Subject is capable and willing to give informed consent
  • Female volunteers of child bearing potential must use oral, injected or implanted hormonal methods of contraception

You may not qualify if:

  • Female volunteer is pregnant or breastfeeding
  • GI diseases, major abdominal surgery
  • Major psychiatric illnesses
  • Volunteers that use drugs affecting the GI tract or the central nervous system
  • Volunteers suffering from endocrine diseases such as diabetes, Cushing's disease, Addison's disease, hypothalamic tumor
  • Volunteers that have undergone surgical procedure for weight loss

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Deloose E, Biesiekierski JR, Vanheel H, Depoortere I, Tack J. Effect of motilin receptor activation on food intake and food timing. Am J Clin Nutr. 2018 Apr 1;107(4):537-543. doi: 10.1093/ajcn/nqx044.

MeSH Terms

Conditions

Obesity

Interventions

ErythromycinSodium Chloride

Condition Hierarchy (Ancestors)

OverweightOvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

MacrolidesPolyketidesLactonesOrganic ChemicalsChloridesHydrochloric AcidChlorine CompoundsInorganic ChemicalsSodium Compounds

Study Officials

  • Jan Tack, Prof

    Universitaire Ziekenhuizen KU Leuven

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
BASIC SCIENCE
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 23, 2016

First Posted

January 19, 2017

Study Start

March 1, 2014

Primary Completion

March 1, 2025

Study Completion

March 1, 2025

Last Updated

July 10, 2024

Record last verified: 2024-07

Data Sharing

IPD Sharing
Will not share